Abstract
Summary
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
The global market for Urokinase Injection was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Urokinase Injection include NDPHARM, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc and LIVZON, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Urokinase Injection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Urokinase Injection by region & country, by Type, and by Application.
The Urokinase Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urokinase Injection.
Market Segmentation
By Company
NDPHARM
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems Inc
LIVZON
Segment by Type:
10000-100000IU
100000-1000000IU
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Urokinase Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Urokinase Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Urokinase Injection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Urokinase Injection was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Urokinase Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Urokinase Injection include NDPHARM, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc and LIVZON, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Urokinase Injection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Urokinase Injection by region & country, by Type, and by Application.
The Urokinase Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urokinase Injection.
Market Segmentation
By Company
NDPHARM
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems Inc
LIVZON
Segment by Type:
10000-100000IU
100000-1000000IU
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Urokinase Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Urokinase Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Urokinase Injection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Urokinase Injection Product Introduction
1.2 Global Urokinase Injection Market Size Forecast
1.2.1 Global Urokinase Injection Sales Value (2019-2030)
1.2.2 Global Urokinase Injection Sales Volume (2019-2030)
1.2.3 Global Urokinase Injection Sales Price (2019-2030)
1.3 Urokinase Injection Market Trends & Drivers
1.3.1 Urokinase Injection Industry Trends
1.3.2 Urokinase Injection Market Drivers & Opportunity
1.3.3 Urokinase Injection Market Challenges
1.3.4 Urokinase Injection Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Urokinase Injection Players Revenue Ranking (2023)
2.2 Global Urokinase Injection Revenue by Company (2019-2024)
2.3 Global Urokinase Injection Players Sales Volume Ranking (2023)
2.4 Global Urokinase Injection Sales Volume by Company Players (2019-2024)
2.5 Global Urokinase Injection Average Price by Company (2019-2024)
2.6 Key Manufacturers Urokinase Injection Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Urokinase Injection Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Urokinase Injection
2.9 Urokinase Injection Market Competitive Analysis
2.9.1 Urokinase Injection Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Urokinase Injection Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urokinase Injection as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 10000-100000IU
3.1.2 100000-1000000IU
3.1.3 Others
3.2 Global Urokinase Injection Sales Value by Type
3.2.1 Global Urokinase Injection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Urokinase Injection Sales Value, by Type (2019-2030)
3.2.3 Global Urokinase Injection Sales Value, by Type (%) (2019-2030)
3.3 Global Urokinase Injection Sales Volume by Type
3.3.1 Global Urokinase Injection Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Urokinase Injection Sales Volume, by Type (2019-2030)
3.3.3 Global Urokinase Injection Sales Volume, by Type (%) (2019-2030)
3.4 Global Urokinase Injection Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Urokinase Injection Sales Value by Application
4.2.1 Global Urokinase Injection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Urokinase Injection Sales Value, by Application (2019-2030)
4.2.3 Global Urokinase Injection Sales Value, by Application (%) (2019-2030)
4.3 Global Urokinase Injection Sales Volume by Application
4.3.1 Global Urokinase Injection Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Urokinase Injection Sales Volume, by Application (2019-2030)
4.3.3 Global Urokinase Injection Sales Volume, by Application (%) (2019-2030)
4.4 Global Urokinase Injection Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Urokinase Injection Sales Value by Region
5.1.1 Global Urokinase Injection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Urokinase Injection Sales Value by Region (2019-2024)
5.1.3 Global Urokinase Injection Sales Value by Region (2025-2030)
5.1.4 Global Urokinase Injection Sales Value by Region (%), (2019-2030)
5.2 Global Urokinase Injection Sales Volume by Region
5.2.1 Global Urokinase Injection Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Urokinase Injection Sales Volume by Region (2019-2024)
5.2.3 Global Urokinase Injection Sales Volume by Region (2025-2030)
5.2.4 Global Urokinase Injection Sales Volume by Region (%), (2019-2030)
5.3 Global Urokinase Injection Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Urokinase Injection Sales Value, 2019-2030
5.4.2 North America Urokinase Injection Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Urokinase Injection Sales Value, 2019-2030
5.5.2 Europe Urokinase Injection Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Urokinase Injection Sales Value, 2019-2030
5.6.2 Asia Pacific Urokinase Injection Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Urokinase Injection Sales Value, 2019-2030
5.7.2 South America Urokinase Injection Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Urokinase Injection Sales Value, 2019-2030
5.8.2 Middle East & Africa Urokinase Injection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Urokinase Injection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Urokinase Injection Sales Value
6.2.1 Key Countries/Regions Urokinase Injection Sales Value, 2019-2030
6.2.2 Key Countries/Regions Urokinase Injection Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Urokinase Injection Sales Value, 2019-2030
6.3.2 United States Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Urokinase Injection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Urokinase Injection Sales Value, 2019-2030
6.4.2 Europe Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Urokinase Injection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Urokinase Injection Sales Value, 2019-2030
6.5.2 China Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Urokinase Injection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Urokinase Injection Sales Value, 2019-2030
6.6.2 Japan Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Urokinase Injection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Urokinase Injection Sales Value, 2019-2030
6.7.2 South Korea Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Urokinase Injection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Urokinase Injection Sales Value, 2019-2030
6.8.2 Southeast Asia Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Urokinase Injection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Urokinase Injection Sales Value, 2019-2030
6.9.2 India Urokinase Injection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Urokinase Injection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 NDPHARM
7.1.1 NDPHARM Company Information
7.1.2 NDPHARM Introduction and Business Overview
7.1.3 NDPHARM Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.1.4 NDPHARM Urokinase Injection Product Offerings
7.1.5 NDPHARM Recent Development
7.2 Wanhua Biochem
7.2.1 Wanhua Biochem Company Information
7.2.2 Wanhua Biochem Introduction and Business Overview
7.2.3 Wanhua Biochem Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Wanhua Biochem Urokinase Injection Product Offerings
7.2.5 Wanhua Biochem Recent Development
7.3 Jiangxi Haoran Bio-Pharma
7.3.1 Jiangxi Haoran Bio-Pharma Company Information
7.3.2 Jiangxi Haoran Bio-Pharma Introduction and Business Overview
7.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Jiangxi Haoran Bio-Pharma Urokinase Injection Product Offerings
7.3.5 Jiangxi Haoran Bio-Pharma Recent Development
7.4 Jiangsu Aidea Pharmaceutical
7.4.1 Jiangsu Aidea Pharmaceutical Company Information
7.4.2 Jiangsu Aidea Pharmaceutical Introduction and Business Overview
7.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Jiangsu Aidea Pharmaceutical Urokinase Injection Product Offerings
7.4.5 Jiangsu Aidea Pharmaceutical Recent Development
7.5 Techpool
7.5.1 Techpool Company Information
7.5.2 Techpool Introduction and Business Overview
7.5.3 Techpool Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Techpool Urokinase Injection Product Offerings
7.5.5 Techpool Recent Development
7.6 Microbic Biosystems Inc
7.6.1 Microbic Biosystems Inc Company Information
7.6.2 Microbic Biosystems Inc Introduction and Business Overview
7.6.3 Microbic Biosystems Inc Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Microbic Biosystems Inc Urokinase Injection Product Offerings
7.6.5 Microbic Biosystems Inc Recent Development
7.7 LIVZON
7.7.1 LIVZON Company Information
7.7.2 LIVZON Introduction and Business Overview
7.7.3 LIVZON Urokinase Injection Sales, Revenue and Gross Margin (2019-2024)
7.7.4 LIVZON Urokinase Injection Product Offerings
7.7.5 LIVZON Recent Development
8 Industry Chain Analysis
8.1 Urokinase Injection Industrial Chain
8.2 Urokinase Injection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Urokinase Injection Sales Model
8.5.2 Sales Channel
8.5.3 Urokinase Injection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer